Baseimmune

Summary

Seedtable Score

44

Locations

• London

Company Size

• 1 to 10

Last Stage Round

• Series A

Industry

• AI
• Biotech

Insights

Baseimmune, based in London, leverages advanced AI to revolutionize vaccine development, offering a competitive edge in the biotech sector. Their B2B SaaS model aligns with industry trends favoring digital transformations and efficiencies. Unlike traditional methods, Baseimmune's AI algorithms enable faster and more effective vaccine creation, addressing issues like delayed outbreak responses. Backed by investors such as Hoxton Ventures and Merck Global Health Innovation Fund, Baseimmune is well-positioned for significant growth and impact in healthcare.

• 2024 Series A $11.4M

---

• 2021 Seed $947k

---

Investors

• Hoxton Ventures Series A

---

• IQ Capital Partners Series A

---

• Maki.vc Series A

---

• Merck Global Health Innovation Fund Series A

---

• Cherry Ventures Seed

---

• Hoxton Ventures Seed

---

• Maki.vc Seed

---

• Creator Fund Seed

---